| Sequential monotherapy(group 1) | Step-up combination therapy (group 2) | Initial combination with prednisone (group 3) | Initial combination with infliximab(group 4) | |
| BMD loss in hands | ||||
| After 1 year | −2.6 (−5.4 to −0.8) | −1.7 (−5.1 to −0.1) | −0.6 (−2.2 to 0.3) | −0.9 (−2.8 to 0.5) |
| After 2 years | −3.6 (−6.8 to −1.4) | −3.3 (−6.8 to −0.2) | −1.4 (−5.4 to −0.1) | −1.6 (−4.7 to 0.3) |
| BMD loss in hip | ||||
| After 1 year | −1.6 (−3.5 to 1.1) | −0.4 (−2.7 to 2.3) | −1.0 (−4.6 to 1.7) | −0.6 (−2.7 to 2.1) |
| After 2 years | −1.1 (−2.9 to 2.0) | −0.2 (−2.6 to 2.3) | −0.2 (−2.6 to 3.2) | −0.6 (−3.3 to 2.0) |
| BMD loss in spine | ||||
| After 1 year | −0.2 (−2.8 to 2.0) | −1.1 (−2.5 to 1.4) | −1.0 (−2.7 to 1.8) | −0.1 (−3.1 to 1.1) |
| After 2 years | −0.4 (−4.6 to 2.6) | −1.6 (−4.6 to 1.1) | −0.5 (−3.9 to 2.1) | −1.0 (−3.3 to 1.4) |
BMD, bone mineral density.